

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## Ocrevus

(ocreluzumab)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this				
Specialty:	* DEA, NPI or TIN:		form are completed.*				
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID:		* Date of Birth:		
Office Fax:			* Patient Street Address:				
Office Street Address:			City: Stat		e:	Zip:	
City:	State:	Zip:	Patient Phone:				
Urgency:         Standard         Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)							
Medication requested:							
☐ Ocrevus 300 mg/10 mL vial							
☐ other (please specify):							
Directions for use: Dose and Quanti J-code:			y:	C	Duration of therapy:		
Frequency of administration:				ICD10:			
Where will this medication be obtained? Accredo Specialty Pharmacy** Hospital Outpatient Retail pharmacy Other (please specify):			<ul> <li>Home Health / Home Infusion vendor</li> <li>Physician's office stock (billing on a medical claim form)</li> <li>**Cigna's nationally preferred specialty pharmacy</li> </ul>				
Is this a new start or continuation of therapy? If your patient has already begun treatment with drug samples of Ocrevus, please choose new start of therapy.							
new start of therapy continuation of therapy							
(if continuation of therapy) Has your patient had a documented beneficial response to this medication?							
(if no) Please provide clinical support for continued use of Ocrevus.							
**Medication orders can be NCPDP 4436920), Fax 888			e - Accredo (1620 C	entury Center Pkv	vy, Memphis, Tl	N 38134-8822	
Facility and/or doctor dispensing and administering medication:							
acility Name: State:		State:	Tax ID#:				
Address (City, State and Zip	p Code):						
Where will this drug be administered? Patient's Home Hospital Outpatient				<ul><li>Physician's Office</li><li>Other (please specify):</li></ul>			
<b>NOTE:</b> Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.							

Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? Yes Ves No (provide medical necessity rationale):

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient?

What is your patient's diagnosis?  Active Secondary Progressive Multiple Sclerosis (SPMS) (for example, SPMS with a documented relapse) Clinically Isolated Syndrome (CIS) Relapsing-Remitting Multiple Sclerosis (RRMS) Primary Progressive Multiple Sclerosis (PPMS) other (please specify):
Clinical Information:
Besides the drug being requested, other disease-modifying agents used for multiple sclerosis include: Aubagio, Avonex, Bafiertam, Betaseron/Extavia, Briumvi, Copaxone/Glatopa, dimethyl fumarate, fingolimod, glatiramer, Gilenya, Kesimpta, Lemtrada, Mavenclad, Mayzent, Plegridy, Ponvory, Rebif, Tascenso ODT, Tysabri, Tecfidera, teriflunomide, Vumerity, and Zeposia. Which of the following best describes your patient's situation? The patient is NOT taking any other drug at this time, nor will they in the future. The requested drug is the only drug the patient is/will be using. The patient is currently on another drug, but this drug will be stopped and the requested drug will be started. The patient is currently on another drug, and the requested drug will be added. The patient may continue to take both drugs together. The patient is currently on BOTH the requested drug AND another drug. (if other/unknown (if other/more than the requested drug) Please provide the rationale for concurrent use.
(if Active SPMS, CIS, or RRMS) Has the patient been treated with ANY MS disease-modifying therapies?
Has your patient tried any of the following? (check all that apply) dimethyl fumarate (generic for Tecfidera) fingolimod (generic for Gilenya)
For the alternatives tried, please include drug name and strength, date(s) taken and for how long, and what the documented results were of taking each drug. For the alternatives NOT tried, please provide details why your patient can't try that drug.
(Please note: there are different preferred products depending on your patient's plan. Please refer to the applicable Cigna health care professional resource [e.g. cignaforhcp.com] to determine benefit availability and the terms and conditions of coverage)
Additional Information: (Please provide any additional pertinent clinical information, including: if the patient is currently on the requested drug (with dates of use) and how they have been receiving it (for example: samples, out of pocket).
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Prescriber Signature: Date:
Save Time! Submit Online at: <u>www.covermymeds.com/main/prior-authorization-forms/cigna/</u> or via SureScripts in your EHR.
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that

you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

NDC number is required on the medical claims to confirm claim is payable for the drug Betaseron. The NDC number can be found on the drug packaging. In addition you may refer to the Crosswalk of HCPCS Codes Requiring NDC on Claims at the Cigna for Health Care Professionals website (CignaforHCP.com > Resources > Clinical Reimbursement Policies and Payment Policies >."

v010124

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005